drugset / Trial / NCT04357782

Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation

NCT04357782

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Previous research has shown that high dose intravenous vitamin C (HDIVC) may benefit patients with sepsis, acute lung injury (ALI), and the acute respiratory distress syndrome (ARDS). However, it is not known if early administration of HDIVC could prevent progression to ARDS. We hypothesize that HDIVC is safe and tolerable in Coronavirus disease 2019 (COVID-19) subjects given early or late in the disease course and may reduce the risk of respiratory failure requiring mechanical ventilation and development of ARDS along with reductions in supplemental oxygen demand and inflammatory markers.

Timeline

Start
2020-04-16
Primary completion
2020-10-13
Completion
2020-10-13

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Vitamin C Other / unclassified 50 mg/kg Intravenous

Indications